7
Participants
Start Date
March 21, 2019
Primary Completion Date
September 15, 2021
Study Completion Date
June 21, 2022
HST-NEETs
The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
Whitman Walker Health Research Department (Wwh), Washington D.C.
Children's National Hospital, Washington D.C.
Children's National Medical Center and WHITMAN WALKER HEALTH RESEARCH DEPARTMENT (WWH), Washington D.C.
Catherine Bollard
OTHER